Replimune Group, Inc. (REPL)
| Market Cap | 450.89M +84.5% |
| Revenue (ttm) | n/a |
| Net Income | -313.94M |
| EPS | -3.38 |
| Shares Out | 83.96M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,415 |
| Open | n/a |
| Previous Close | 5.41 |
| Day's Range | n/a |
| 52-Week Range | 1.50 - 12.50 |
| Beta | 0.87 |
| Analysts | Hold |
| Price Target | 10.67 (+98.7%) |
| Earnings Date | Aug 3, 2026 |
About REPL
Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer in the United States and the United Kingdom. The company’s proprietary oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF for a range of solid tumors. The company is also developing RP2 that expresses an an... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 8 analysts, the average rating for REPL stock is "Hold." The 12-month stock price target is $10.67, which is an increase of 98.70% from the latest price.
News
Replimune confirms FDA AdCom voted in favor of experimental melanoma treatment
The company states: “Replimune (REPL) announced the outcome of today’s meeting of the U.S. Food and Drug Administration’s (FDA) Cellular, Tissue, and Gene Therapies Advisory Committee, or CTGTAC, whic...
Replimune Announces Favorable Outcome of FDA's Cellular, Tissue, and Gene Therapies Advisory Committee Meeting for RP1 in Advanced Melanoma
WOBURN, Mass., July 30, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical-stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today annou...
FDA panel votes 10-3 in favor of Replimune’s experimental melanoma treatment
17:42 EDT FDA panel votes 10-3 in favor of Replimune’s (REPL) experimental melanoma treatment
A Food and Drug Administration advisory panel voted 10-3 for Replimune Group's experimental melanoma therapy, after experts raised doubts about whether the company's data and trial design could be trusted to show the drug works
Independent experts voted 10-3 despite regulators' concern about the design of the company's pivotal cancer trial.
US FDA panel backs Replimune skin cancer drug study data
A panel of outside advisers to the US Food and Drug Administration voted to back results from a trial studying Replimune's drug for a type of skin cancer in a meeting on Thursday.
Replimune Group Proxy statement: Proxy filing
Replimune Group filed a proxy statement on July 29, 2026, providing details for shareholder voting and corporate governance matters.
Replimune Group Proxy statement: Proxy filing
Replimune Group filed a proxy statement on July 29, 2026, providing details for shareholder voting and corporate governance matters.
Replimune Group, Inc. (REPL) Investors Who Suffered Losses Are Encouraged to Contact Johnson Fistel Following FDA Briefing Document
SAN DIEGO, July 28, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating whether Replimune Group, Inc. (NASDAQ: REPL) or certain of its executive officers violated state or federal securitie...
BMO sees ‘uphill battle’ for Replimune at Thursday’s FDA panel meeting
BMO Capital analyst Evan Seigerman says Replimune’s (REPL) FDA briefing documents “read negatively.” The FDA continues to highlight concerns around contributions of components and treatment population...
Replimune sinks after FDA briefing documents question RP1 data
Shares of Replimune (REPL) are moving lower the FDA posted briefing documents for its panel meeting on vusolimogene oderparepvec, RP1, in combination with nivolumab for the treatment of adult patients...
US FDA staff raise efficacy concerns on Replimune's skin cancer drug ahead of meeting
The U.S. FDA staff reviewers raised concerns on the efficacy of Replimune's drug for a type of a skin cancer, ahead of their meeting on July 30, briefing documents showed on Tuesday.
Replimune Group put volume heavy and directionally bearish
Bearish flow noted in Replimune (REPL) Group with 6,933 puts trading, or 3x expected. Most active are 8/7 weekly 8.5 calls and 8/28 weekly 20 puts, with total volume in…
Replimune Group Registration statement: Registration filing
Replimune Group filed a registration statement on July 24, 2026, providing details about a securities offering with the SEC.
Replimune Group put volume heavy and directionally bearish
Bearish flow noted in Replimune (REPL) Group with 3,199 puts trading, or 1.5x expected. Most active are Sep-26 18 puts and Aug-26 8 puts, with total volume in those strikes…
Johnson Fistel, PLLP Investigates Claims on Behalf of Long-Term Shareholders of Replimune Group, Inc. (REPL)
SAN DIEGO, July 15, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of current, long-term shareholders of Replimune Group, Inc. (NASDAQ: REPL) against certain...
Replimune Group Proxy statement: Proxy filing
Replimune Group filed a proxy statement on July 13, 2026, providing details for shareholder voting and corporate governance matters.
Replimune Group put volume heavy and directionally bearish
Bearish flow noted in Replimune (REPL) Group with 2,615 puts trading, or 1.8x expected. Most active are Aug-26 7 puts and 8/7 weekly 15 calls, with total volume in those…
Replimune Group put volume heavy and directionally bearish
Bearish flow noted in Replimune (REPL) Group with 5,913 puts trading, or 3x expected. Most active are 8/14 weekly 8 puts and 8/7 weekly 8 puts, with total volume in…
Replimune price target raised to $9 from $6 at Wedbush
Wedbush raised the firm’s price target on Replimune (REPL) to $9 from $6 and keeps a Neutral rating on the shares. The firm notes the company reported fiscal fourth quarter…
BMO double upgrades Replimune on higher chances of FDA approval
BMO Capital double upgraded Replimune (REPL) to Outperform from Underperform with a price target of $16, up from $1. The FDA’s acceptance of Replimune’s re-filed application increased confidence in RP...
Replimune Group put volume heavy and directionally bearish
Bearish flow noted in Replimune (REPL) Group with 1,899 puts trading, or 1.4x expected. Most active are Aug-26 7 puts and Aug-26 15 calls, with total volume in those strikes…
Replimune Reports Fiscal Fourth Quarter and Year End 2026 Financial Results and Provides Corporate Update
WOBURN, Mass., June 29, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today annou...
Replimune Group Earnings release: Q4 2026
Replimune Group released its Q4 2026 earnings on June 29, 2026, summarizing the period's financial results.
Replimune Group Annual report: Q4 2026
Replimune Group has published its Q4 2026 annual report on June 29, 2026.
JPMorgan upgrades Replimune on RP1 application resubmission
JPMorgan upgraded Replimune (REPL) to Overweight from Neutral with a price target of $17, up from $8, after the company announced that the RP1 biologics license application resubmission has been…